[HTML][HTML] CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer
RJ Lim, R Salehi-Rad, LM Tran, MS Oh, C Dumitras… - Cell Reports …, 2024 - cell.com
Immune checkpoint blockade (ICB) with PD-1/PD-L1 inhibition has revolutionized the
treatment of non-small cell lung cancer (NSCLC). Durable responses, however, are …
treatment of non-small cell lung cancer (NSCLC). Durable responses, however, are …
Inhibition of NETosis via PAD4 alleviated inflammation in giant cell myocarditis
Z Hu, X Hua, X Mo, Y Chang, X Chen, Z Xu, M Tao… - Iscience, 2023 - cell.com
Giant cell myocarditis (GCM) is a rare, usually rapidly progressive, and potentially fatal
disease. Detailed inflammatory responses remain unknown, in particular the formation of …
disease. Detailed inflammatory responses remain unknown, in particular the formation of …
Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma
CX Huang, XM Lao, XY Wang, YZ Ren, YT Lu, W Shi… - Cancer Cell, 2024 - cell.com
Hyperprogressive disease can occur in cancer patients receiving immune checkpoint
blockade (ICB) therapy, but whether and how reactive cytotoxic T lymphocytes (CTLs) exert …
blockade (ICB) therapy, but whether and how reactive cytotoxic T lymphocytes (CTLs) exert …
Distinct immune signatures for predicting the immunotherapy efficacy of esophageal squamous cell carcinoma or adenocarcinoma
P Wu, G Qin, J Liu, Q Zhao, X Zhao, X Song… - Cancer Immunology …, 2025 - Springer
Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are
distinct histological subtypes of esophageal cancer. The tumor microenvironment of each …
distinct histological subtypes of esophageal cancer. The tumor microenvironment of each …
[HTML][HTML] Membrane-localized neoantigens predict the efficacy of cancer immunotherapy
Z Goldberger, S Hauert, K Chang, T Kurtanich… - Cell Reports …, 2023 - cell.com
Immune checkpoint immunotherapy (ICI) can re-activate immune reactions against
neoantigens, leading to remarkable remission in cancer patients. Nevertheless, only a …
neoantigens, leading to remarkable remission in cancer patients. Nevertheless, only a …
IL7 in combination with radiotherapy stimulates a memory T-cell response to improve outcomes in HNSCC models
J Yu, J Gadwa, RB Ross, M Knitz, LB Darragh… - Cancer Immunology …, 2024 - Springer
Clinically approved head and neck squamous cell carcinoma (HNSCC) immunotherapies
manipulate the immune checkpoint blockade (ICB) axis but have had limited success …
manipulate the immune checkpoint blockade (ICB) axis but have had limited success …
Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity
W Shi, N Liu, Z Liu, Y Yang, Q Zeng, Y Wang… - Cell Reports …, 2024 - cell.com
The clinical applications of immunocytokines are severely restricted by dose-limiting
toxicities. To address this challenge, here we propose a next-generation immunocytokine …
toxicities. To address this challenge, here we propose a next-generation immunocytokine …
[HTML][HTML] Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models
DE Tsai, A Lovanov, A Abdelmaksoud, J Akhtar… - Iscience, 2024 - cell.com
SET and MYND-domain containing protein 3 (SMYD3) mediates epigenetic repression of
type I IFN response genes in human papillomavirus (HPV)-negative HNSCC cells, and …
type I IFN response genes in human papillomavirus (HPV)-negative HNSCC cells, and …